Prostaglandin synthesis modulation

Prostaglandin synthesis modulation" is not a specific molecule or receptor but rather refers to the process by which the biosynthesis and activity of **prostaglandins**—a class of lipid mediators derived from arachidonic acid—are regulated or pharmacologically targeted. The key molecular targets in this pathway are enzymes such as **cyclooxygenases** (COX‑1 and COX‑2) and various terminal synthases including **microsomal prostaglandin E synthase 1** (mPGES‑1)[1][4][5]. These enzymes catalyze sequential steps converting arachidonic acid into different bioactive prostanoids like PGE₂, PGI₂, PGD₂, PGF₂α, and thromboxane A₂. Drugs that modulate this pathway—including NSAIDs and selective enzyme inhibitors—are widely used for their anti-inflammatory, analgesic, antipyretic, and antithrombotic effects but can also cause significant adverse effects depending on the specificity and extent of inhibition within the pathway. Because "prostaglandin synthesis modulation" is a process rather than a discrete target molecule or protein family member (such as an enzyme or receptor), it should not be considered a canonical therapeutic target itself; instead, its components are valid drug targets individually[2][5]. > "Prostaglandins are produced following the sequential oxygenation of arachidonic acid...by cyclooxygenases (COX–1 and COX–2) and terminal prostaglandin syntheses...Drugs that inhibit these enzymes modulate inflammation..." [1][3] > "NSAIDs...ameliorate pain...by inhibiting COX...the rate-limiting enzyme in the biosynthetic cascade..." [2] Because this entry describes a biological process rather than an individual molecular entity suitable for structured drug-target information mapping—and does not correspond to a single gene product—it is marked as incorrect for use as a canonical target entry.

Other names

Modulation of prostaglandin synthesisRegulation of prostaglandin biosynthesisProstaglandin pathway modulation

Inhibition of cyclooxygenase enzymes (COX‑1 and COX‑2), reducing prostaglandin production\nInhibition of microsomal prostaglandin E synthase‑1 (mPGES‑1), reducing PGE₂ levels